Healthcare Industry News:  MediciNova 

Biopharmaceuticals Personnel

 News Release - September 1, 2006

MediciNova, Inc. Appoints Mr. Masatsune Okajima as Vice President and Head of Japanese Office

SAN DIEGO, Sept. 1 (HSMN NewsFeed) -- MediciNova, Inc., a pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the appointment of Mr. Okajima as Vice President and Head of Japanese Office, effective September 1, 2006.

Since 2002, Mr. Okajima has served as Deputy General Manager, Daiwa Securities SMBC Co., Ltd. From 1999 through 2002, Mr. Okajima served as General Deputy Manager, SB Capital Markets Co., Ltd. (currently Daiwa Securities SMBC Co., Ltd.). From 1996 to 1999, Mr. Okajima served as Manager, Sumitomo Capital Securities Co., Ltd. Mr. Okajima served in various positions at Sumitomo Bank, Ltd. (currently Mitsui Sumitomo Bank) between 1991 and 1996. In 1991, Mr. Okajima graduated with a B.S. Degree from the Department of Science and Technology, Tokyo Science University.

About MediciNova

MediciNova, Inc. is a publicly traded pharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical products. MediciNova's pipeline, which includes several compounds in clinical testing, targets a variety of prevalent medical conditions, including cancer, asthma, Generalized Anxiety Disorder, multiple sclerosis, interstitial cystitis, status asthmaticus, preterm labor and urinary incontinence. For more information on MediciNova, Inc., please visit www.MediciNova.com.


Source: MediciNova

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.